FUNDAMENTALS · Fundamentals · JP Healthcare

JMDC (4483) Fundamentals 2026 — P/E 31.8x, Revenue Analysis | SniperIQ

JMDC (4483) is a JP-listed Healthcare company in Medical - Healthcare Information Services with a market capitalization of ¥215.3B, trading at ¥3290.00 on the JPX. This SniperIQ fundamentals page covers JMDC's valuation (P/E 31.8x, P/B 2.6x), profitability (net margin 13.4%), revenue (¥50.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap¥215.3B
P/E (TTM)31.8x
Net Margin13.4%
Revenue (FY25)¥50.5B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is JMDC's market cap?

JMDC (4483) has a market capitalization of approximately ¥215.3B, trading at ¥3290.00 on the JPX. Market cap moves with the live share price.

What is JMDC's P/E ratio?

JMDC's trailing twelve-month P/E ratio is 31.8x, with a price-to-book (P/B) of 2.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is JMDC?

JMDC runs a net profit margin of 13.4%, a gross margin of 54.9%, and an operating margin of 19.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does JMDC generate?

JMDC reported revenue of ¥50.5B for fiscal year 2025, with net income of ¥6.8B and earnings per share (EPS) of 103.43. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does JMDC pay a dividend?

JMDC offers a trailing dividend yield of about 0.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is JMDC financially healthy?

JMDC carries a debt-to-equity ratio of 0.62x and a current ratio of 2.27x, with a market beta of 0.82. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is JMDC a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For JMDC (4483) the key facts are: market cap ¥215.3B, P/E 31.8x, revenue ¥50.5B, 52-week range 2369-4950. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track JMDC's full fundamentals live

Get JMDC's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Bio Plus (099430) fundamentals · Create SD Holdings (3148) fundamentals · Yungjin Pharm (003520) fundamentals · Novo Nordisk (NVO) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons